Investing on the edge
Back to Top

Simply what every other Venture Capital firm does is not

We believe that being thesis driven, research-intensive, bold and convicted will produce long-term outperformance.

Gravity Fund is a purely thesis-driven, research-intensive early-stage investment fund based in Minneapolis that’s exploring the frontier of technology on the brink of changing the world. Our team has a successful track record seed-stage investing under two defined theses- Next Iteration of the Internet and Engineered Biology. The investing environment in our areas of focus has never been better.

We utilize our domain expertise, and take a deep hands-on approach to uniquely understand and creatively solve for the problems of our ambitious founders and companies, adding value every step of the way to help projects reach their full potential.

Pushing the Frontier

The next iteration of the internet

The next iteration of the internet promises to be a dynamic fusion of Web3, the Metaverse, and advanced AI, heralding a transformative era of connectivity and interaction. Web3, built on decentralized technologies, aims to democratize online spaces by empowering users with greater control over their data and digital identities, reshaping traditional models of commerce, governance, and social interaction.

The Metaverse, a collective of 3D virtual social spaces blurs the boundaries between physical and digital realms. Powered by immersive technologies like virtual reality (VR) and augmented reality (AR), the Metaverse transcends conventional static 2D internet experiences. Within this expansive digital universe, individuals can engage in a myriad of activities ranging from socializing, gaming, and entertainment to education, work, and commerce.

AI plays a pivotal role in shaping the next iteration of the internet, driving personalized experiences, intelligent automation, easy-to-use creator tools and lifelike non-player-characters (NPCs). Together, Web3, the Metaverse, and AI converge to redefine the internet as a decentralized, immersive, and intelligent ecosystem, unlocking unprecedented possibilities for collaboration, creativity, and connectivity.

Engineered Biology

We believe that the the next decade will mark a pivotal era for biotechnology, akin to the transformative period that the 1970s represented for computing. Just as the advent of personal computers revolutionized access to computing power, democratized access to advanced tools in biotech, such as computational biology, gene editing technologies, sophisticated bioreactors, and protein engineering platforms, is poised to significantly lower the entry barriers to drug development.

These advanced tools empower small teams of researchers to undertake tasks that were once the domain of large pharmaceutical companies or specialized research institutions. Tasks such as target predictions, molecule design, and drug screening can now be iterated upon with unprecedented speed and efficiency. The exponential decrease in the cost of utilizing these tools has made it increasingly feasible for startups to engage in groundbreaking research and development endeavors.

The convergence of these factors creates a fertile environment for innovation in biotechnology. We anticipate witnessing a proliferation of novel therapies, diagnostics, and biotechnological solutions that address a diverse array of medical challenges. As we embark on this exciting journey, the next decade holds promise as a decade of unparalleled progress and breakthroughs in the field of biotechnology.

Let’s Build the Future Together.